RISE-IIP: some pitfalls and observations

Affiliations

¹ U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria e Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS, Milan 20123, Italy. Electronic address: sharari@ilpolmone.it.

Free article

Comment

Sergio Harari. Lancet Respir Med. 2019 Nov.

Free article

. 2019 Nov;7(11):e35.

doi: 10.1016/S2213-2600(19)30378-9.

¹ U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria e Emodinamica Polmonare, Ospedale San Giuseppe, MultiMedica IRCCS, Milan 20123, Italy. Electronic address: sharari@ilpolmone.it.

No abstract available

Comment on

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Boateng F, Wells AU. Nathan SD, et al. Lancet Respir Med. 2019 Sep;7(9):780-790. doi: 10.1016/S2213-2600(19)30250-4. Epub 2019 Aug 12. Lancet Respir Med. 2019. PMID: 31416769 Clinical Trial.